{"id":9048,"date":"2023-10-13T10:14:23","date_gmt":"2023-10-13T08:14:23","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&p=9048"},"modified":"2024-04-30T13:49:26","modified_gmt":"2024-04-30T11:49:26","slug":"real-world-effectiveness-and-safety-of-advanced-therapies-for-the-treatment-of-moderate-to-severe-ulcerative-colitis-uc-evidence-from-a-systematic-literature-review-slr","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/es\/professional\/scientific-corner\/real-world-effectiveness-and-safety-of-advanced-therapies-for-the-treatment-of-moderate-to-severe-ulcerative-colitis-uc-evidence-from-a-systematic-literature-review-slr\/","title":{"rendered":"Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis (UC): evidence from a systematic literature review (SLR)"},"content":{"rendered":"
\n

Makoto Naganuma<\/a>\u00a01<\/a><\/sup>,\u00a0Taku Kobayashi<\/a>\u00a02<\/a><\/sup>,\u00a0Reiko Kunisaki<\/a>\u00a03<\/a><\/sup>,\u00a0Katsuyoshi Matsuoka<\/a>\u00a04<\/a><\/sup>,\u00a0Shojiro Yamamoto<\/a>\u00a05<\/a><\/sup>,\u00a0Ami Kawamoto<\/a>\u00a06<\/a><\/sup>,\u00a0Daisuke Saito<\/a>\u00a07<\/a><\/sup>,\u00a0Kosaku Nanki<\/a>\u00a08<\/a><\/sup>,\u00a0Kazuyuki Narimatsu<\/a>\u00a09<\/a><\/sup>,\u00a0Hisashi Shiga<\/a>\u00a010<\/a><\/sup>,\u00a0Motohiro Esaki<\/a>\u00a011<\/a><\/sup>,\u00a0Shinichiro Yoshioka<\/a>\u00a012<\/a><\/sup>,\u00a0Shingo Kato<\/a>\u00a013<\/a><\/sup>,\u00a0Masayuki Saruta<\/a>\u00a014<\/a><\/sup>,\u00a0Shinji Tanaka<\/a>\u00a015<\/a><\/sup>,\u00a0Eriko Yasutomi<\/a>\u00a016<\/a><\/sup>,\u00a0Kaoru Yokoyama<\/a>\u00a017<\/a><\/sup>,\u00a0Kei Moriya<\/a>\u00a018<\/a><\/sup>,\u00a0Yoshikazu Tsuzuki<\/a>\u00a019<\/a><\/sup>,\u00a0Makoto Ooi<\/a>\u00a020<\/a><\/sup>,\u00a0Mikihiro Fujiya<\/a>\u00a021<\/a><\/sup>,\u00a0Atsushi Nakazawa<\/a>\u00a022<\/a><\/sup>,\u00a0Takayuki Abe<\/a>\u00a023<\/a><\/sup>,\u00a0Tadakazu Hisamatsu<\/a>\u00a06<\/a><\/sup>;\u00a0Japanese UC Study Group<\/a> J Gastroenterol.\u00a02023 Dec;58(12):1198-1210.\u00a0doi: 10.1007\/s00535-023-02048-w.\u00a0<\/p>\n<\/div>\n\n

\n

Background: <\/strong>This multicenter observational cohort study aimed to evaluate the utilization and short-term efficacy of advanced therapy (AT) in hospitalized patients with acute severe ulcerative colitis (ASUC).<\/p>\n<\/div>\n\n

\n

Methods: <\/strong>In total, 221 patients with ASUC were enrolled between August 2020 and July 2021. The primary endpoint was clinical remission (CR, defined as a patient-reported outcome score < 2 with no blood in the stool) rate on Day 7 and 14 in hospitalized patients who received corticosteroids (CS) and AT.<\/p>\n<\/div>\n\n

\n

Results: <\/strong>Among patients with ASUC, 120 and 101 patients received CS or any AT as first-line treatment, respectively. The CR rates on Day 7 and 14 were 22.5% and 35.0%, respectively, in hospitalized patients who received CS as first-line treatment. Most patients who used ATs had CS-dependent or frequent recurrences. Eight different ATs (apheresis, tacrolimus, infliximab, golimumab, tofacitinib, vedolizumab, ustekinumab, and cyclosporine) were used as first-line treatment in patients with ASUC, and the CR rates on Day 7 and 14 were 16.8% and 29.7%, respectively. Twenty-five patients received the second ATs after hospitalizations, and the CR rates on Day 7 and 14 were 0% and 12%, respectively. The CR rates on Day 14 were significantly higher in patients who changed to AT than in those whose dose of CS increased (34.0% vs 10.7%, p = 0.020) among patients who had already used CS before hospitalization.<\/p>\n<\/div>\n\n

\n

Conclusion:\u00a0<\/strong>Most first-use ATs were effective for patients with ASUC, while second-use ATs might have had limited benefits in inducing CR. These findings may contribute to considerations for the management of hospitalized patients.<\/p>\n<\/div>\n\n

\n

Real-world efficacy and safety of advanced therapies in hospitalized patients with ulcerative colitis – PubMed (nih.gov)<\/a><\/p>\n<\/div>\n\n

\n

Real-world efficacy and safety of advanced therapies in hospitalized patients with ulcerative colitis | Journal of Gastroenterology (springer.com)<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Makoto Naganuma\u00a01,\u00a0Taku Kobayashi\u00a02,\u00a0Reiko Kunisaki\u00a03,\u00a0Katsuyoshi Matsuoka\u00a04,\u00a0Shojiro Yamamoto\u00a05,\u00a0Ami Kawamoto\u00a06,\u00a0Daisuke Saito\u00a07,\u00a0Kosaku Nanki\u00a08,\u00a0Kazuyuki Narimatsu\u00a09,\u00a0Hisashi Shiga\u00a010,\u00a0Motohiro Esaki\u00a011,\u00a0Shinichiro Yoshioka\u00a012,\u00a0Shingo Kato\u00a013,\u00a0Masayuki Saruta\u00a014,\u00a0Shinji Tanaka\u00a015,\u00a0Eriko Yasutomi\u00a016,\u00a0Kaoru Yokoyama\u00a017,\u00a0Kei Moriya\u00a018,\u00a0Yoshikazu Tsuzuki\u00a019,\u00a0Makoto Ooi\u00a020,\u00a0Mikihiro Fujiya\u00a021,\u00a0Atsushi Nakazawa\u00a022,\u00a0Takayuki Abe\u00a023,\u00a0Tadakazu Hisamatsu\u00a06;\u00a0Japanese UC Study Group J Gastroenterol.\u00a02023 Dec;58(12):1198-1210.\u00a0doi: 10.1007\/s00535-023-02048-w.\u00a0 Background: This multicenter observational cohort study aimed to evaluate the utilization and short-term efficacy of advanced therapy (AT) in hospitalized patients with acute severe […]<\/p>\n","protected":false},"template":"","scientific_tags":[757,147,346,486,157,424,758,109,627,100,269,156,485,271,756,352,450,306,88,66],"class_list":["post-9048","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-asuc","scientific_tags-clinical-remission","scientific_tags-cohort","scientific_tags-cyclosporine","scientific_tags-efficacy","scientific_tags-gma","scientific_tags-golimumab","scientific_tags-infliximab","scientific_tags-moderate-to-severe","scientific_tags-multicenter","scientific_tags-observational","scientific_tags-safety","scientific_tags-steoids","scientific_tags-study","scientific_tags-systematic-literature-review","scientific_tags-tacrolimus","scientific_tags-tofacitinib","scientific_tags-ulcerative-colitis","scientific_tags-ustekinumab","scientific_tags-vedolizumab"],"acf":{"sc_authors":"https:\/\/link.springer.com\/article\/10.1007\/s00535-023-02048-w<\/a>"},"yoast_head":"\nReal-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis (UC): evidence from a systematic literature review (SLR) - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/real-world-effectiveness-and-safety-of-advanced-therapies-for-the-treatment-of-moderate-to-severe-ulcerative-colitis-uc-evidence-from-a-systematic-literature-review-slr\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis (UC): evidence from a systematic literature review (SLR) - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Makoto Naganuma\u00a01,\u00a0Taku Kobayashi\u00a02,\u00a0Reiko Kunisaki\u00a03,\u00a0Katsuyoshi Matsuoka\u00a04,\u00a0Shojiro Yamamoto\u00a05,\u00a0Ami Kawamoto\u00a06,\u00a0Daisuke Saito\u00a07,\u00a0Kosaku Nanki\u00a08,\u00a0Kazuyuki Narimatsu\u00a09,\u00a0Hisashi Shiga\u00a010,\u00a0Motohiro Esaki\u00a011,\u00a0Shinichiro Yoshioka\u00a012,\u00a0Shingo Kato\u00a013,\u00a0Masayuki Saruta\u00a014,\u00a0Shinji Tanaka\u00a015,\u00a0Eriko Yasutomi\u00a016,\u00a0Kaoru Yokoyama\u00a017,\u00a0Kei Moriya\u00a018,\u00a0Yoshikazu Tsuzuki\u00a019,\u00a0Makoto Ooi\u00a020,\u00a0Mikihiro Fujiya\u00a021,\u00a0Atsushi Nakazawa\u00a022,\u00a0Takayuki Abe\u00a023,\u00a0Tadakazu Hisamatsu\u00a06;\u00a0Japanese UC Study Group J Gastroenterol.\u00a02023 Dec;58(12):1198-1210.\u00a0doi: 10.1007\/s00535-023-02048-w.\u00a0 Background: This multicenter observational cohort study aimed to evaluate the utilization and short-term efficacy of advanced therapy (AT) in hospitalized patients with acute severe […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/real-world-effectiveness-and-safety-of-advanced-therapies-for-the-treatment-of-moderate-to-severe-ulcerative-colitis-uc-evidence-from-a-systematic-literature-review-slr\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-30T11:49:26+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/real-world-effectiveness-and-safety-of-advanced-therapies-for-the-treatment-of-moderate-to-severe-ulcerative-colitis-uc-evidence-from-a-systematic-literature-review-slr\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/real-world-effectiveness-and-safety-of-advanced-therapies-for-the-treatment-of-moderate-to-severe-ulcerative-colitis-uc-evidence-from-a-systematic-literature-review-slr\/\",\"name\":\"Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis (UC): evidence from a systematic literature review (SLR) - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2023-10-13T08:14:23+00:00\",\"dateModified\":\"2024-04-30T11:49:26+00:00\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/real-world-effectiveness-and-safety-of-advanced-therapies-for-the-treatment-of-moderate-to-severe-ulcerative-colitis-uc-evidence-from-a-systematic-literature-review-slr\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis (UC): evidence from a systematic literature review (SLR) - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/real-world-effectiveness-and-safety-of-advanced-therapies-for-the-treatment-of-moderate-to-severe-ulcerative-colitis-uc-evidence-from-a-systematic-literature-review-slr\/","og_locale":"es_ES","og_type":"article","og_title":"Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis (UC): evidence from a systematic literature review (SLR) - Adacyte","og_description":"Makoto Naganuma\u00a01,\u00a0Taku Kobayashi\u00a02,\u00a0Reiko Kunisaki\u00a03,\u00a0Katsuyoshi Matsuoka\u00a04,\u00a0Shojiro Yamamoto\u00a05,\u00a0Ami Kawamoto\u00a06,\u00a0Daisuke Saito\u00a07,\u00a0Kosaku Nanki\u00a08,\u00a0Kazuyuki Narimatsu\u00a09,\u00a0Hisashi Shiga\u00a010,\u00a0Motohiro Esaki\u00a011,\u00a0Shinichiro Yoshioka\u00a012,\u00a0Shingo Kato\u00a013,\u00a0Masayuki Saruta\u00a014,\u00a0Shinji Tanaka\u00a015,\u00a0Eriko Yasutomi\u00a016,\u00a0Kaoru Yokoyama\u00a017,\u00a0Kei Moriya\u00a018,\u00a0Yoshikazu Tsuzuki\u00a019,\u00a0Makoto Ooi\u00a020,\u00a0Mikihiro Fujiya\u00a021,\u00a0Atsushi Nakazawa\u00a022,\u00a0Takayuki Abe\u00a023,\u00a0Tadakazu Hisamatsu\u00a06;\u00a0Japanese UC Study Group J Gastroenterol.\u00a02023 Dec;58(12):1198-1210.\u00a0doi: 10.1007\/s00535-023-02048-w.\u00a0 Background: This multicenter observational cohort study aimed to evaluate the utilization and short-term efficacy of advanced therapy (AT) in hospitalized patients with acute severe […]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/real-world-effectiveness-and-safety-of-advanced-therapies-for-the-treatment-of-moderate-to-severe-ulcerative-colitis-uc-evidence-from-a-systematic-literature-review-slr\/","og_site_name":"Adacyte","article_modified_time":"2024-04-30T11:49:26+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/real-world-effectiveness-and-safety-of-advanced-therapies-for-the-treatment-of-moderate-to-severe-ulcerative-colitis-uc-evidence-from-a-systematic-literature-review-slr\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/real-world-effectiveness-and-safety-of-advanced-therapies-for-the-treatment-of-moderate-to-severe-ulcerative-colitis-uc-evidence-from-a-systematic-literature-review-slr\/","name":"Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis (UC): evidence from a systematic literature review (SLR) - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2023-10-13T08:14:23+00:00","dateModified":"2024-04-30T11:49:26+00:00","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/real-world-effectiveness-and-safety-of-advanced-therapies-for-the-treatment-of-moderate-to-severe-ulcerative-colitis-uc-evidence-from-a-systematic-literature-review-slr\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner\/9048","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/media?parent=9048"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific_tags?post=9048"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}